JP2024534517A5 - - Google Patents

Info

Publication number
JP2024534517A5
JP2024534517A5 JP2024517482A JP2024517482A JP2024534517A5 JP 2024534517 A5 JP2024534517 A5 JP 2024534517A5 JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024534517 A5 JP2024534517 A5 JP 2024534517A5
Authority
JP
Japan
Prior art keywords
morphology
pharmaceutically acceptable
solvate
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/044232 external-priority patent/WO2023049168A1/en
Publication of JP2024534517A publication Critical patent/JP2024534517A/ja
Publication of JP2024534517A5 publication Critical patent/JP2024534517A5/ja
Pending legal-status Critical Current

Links

JP2024517482A 2021-09-21 2022-09-21 Erbb阻害剤としての多形 Pending JP2024534517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
US63/246,451 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (2)

Publication Number Publication Date
JP2024534517A JP2024534517A (ja) 2024-09-20
JP2024534517A5 true JP2024534517A5 (cg-RX-API-DMAC10.html) 2025-09-30

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517482A Pending JP2024534517A (ja) 2021-09-21 2022-09-21 Erbb阻害剤としての多形

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Similar Documents

Publication Publication Date Title
TWI309647B (cg-RX-API-DMAC10.html)
JP2022186995A5 (cg-RX-API-DMAC10.html)
US8703967B2 (en) Crystal form of sunitinib malate
JP2022049005A5 (cg-RX-API-DMAC10.html)
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
JP2016528179A5 (cg-RX-API-DMAC10.html)
CN114437077B (zh) 用作激酶抑制剂的化合物及其应用
CN110590749B (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
US8372856B2 (en) Hydrates of erlotinib hydrochloride
US12390468B2 (en) Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide
US12187707B2 (en) Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof
EA002836B1 (ru) Безводные и моногидратные формы n-(3-этинилфениламино)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата
JP2021524835A5 (cg-RX-API-DMAC10.html)
TWI443095B (zh) 新穎鹽
CN119110799A (zh) 作为erbb抑制剂的多晶型物
TWI705962B (zh) 喹唑啉衍生物之鹽或其結晶及彼等之製造方法
JP6928964B2 (ja) N−(2−(2−(ジメチルアミノ)エトキシ)−4−メトキシ−5−((4−(1−メチル−1h−インドール−3−イル)ピリミジン−2−イル)アミノ)フェニル)アクリルアミドの薬学的塩およびそれらの結晶形
JP2025517634A5 (cg-RX-API-DMAC10.html)
US20150307484A1 (en) Crystal Form of Dabrafenib and Preparation Method and Use Thereof
JP2022530028A5 (cg-RX-API-DMAC10.html)
JP2022511495A5 (cg-RX-API-DMAC10.html)
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
WO2016098070A1 (en) Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
JP2023548605A5 (cg-RX-API-DMAC10.html)
RU2024110241A (ru) Конденсированное бицикличное производное, его фармацевтически приемлемые соль, кристаллическая форма и способ их получения